

From: [REDACTED]@ipmlp.com>
Sent: vendredi 13 mars 2020 19:51
To: OJALA Annukka (CAB-KYRIAKIDES)
Cc: [REDACTED] (CAB-KYRIAKIDES)
Subject: RE: Altimune - coronavirus intranasal spray vaccine development - need for resources

Dear Annukka,

An important update: Altimune is now in discussions with an EU manufacturer to potentially manufacture and supply the vaccine to Europe. Who would be the right people to speak to jointly coordinate effort on the EU level (funding, requirements, etc.)? I would be thankful for timely introduction to move the effort forward on the EU side as well.

Kind regards,

[REDACTED]

From: [REDACTED]@ec.europa.eu [REDACTED]@ec.europa.eu>
Sent: Friday, March 13, 2020 09:30
To: [REDACTED]@ipmlp.com>
Cc: [REDACTED]@ec.europa.eu
Subject: RE: Altimune - coronavirus intranasal spray vaccine development - need for resources

Dear [REDACTED],

On behalf of Commissioner Kyriakides, I would like to thank you for your message and information you have provided. We have shared this with colleagues in the Directorate-General for Health and Food Safety.

Kind regards,

Annukka

Annukka Ojala
Deputy Head of Cabinet



European Commission
Cabinet of Commissioner Stella Kyriakides
Health and Food Safety
Rue de la Loi 200, BERL 1 [REDACTED]
B-1049 Brussels/Belgium

Telephone: +32 [REDACTED]
Email: [REDACTED]@ec.europa.eu

From: [REDACTED]@ipmlp.com>
Date: March 5, 2020 at 00:00:53 GMT+1
To: [REDACTED] (CAB-SEFCOVIC)"
[REDACTED]@ec.europa.eu>, "KYRIAKIDES Stella
(CAB-KYRIAKIDES)" [REDACTED]@ec.europa.eu>
**Subject: RE: Altimune - coronavirus intranasal spray
vaccine development - need for resources**

Dear Ms. Kyriakides,

Nice to meet you via email. We are already talking to the US government task force about the best pathway forward to create a promising option and to coordinate the effort. If interested, happy to talk to you and your EU team as well. Happy to get on the phone at your convenience or to introduce you to the company directly to save time.

Kind regards,

[REDACTED]

<image001.jpg>

[REDACTED]
2181 Greenwich Street | San Francisco, CA 94123
m: (919) 308.4932 | [REDACTED]@presidiopartners.com

From: [REDACTED]@ec.europa.eu
[REDACTED]@ec.europa.eu>
Sent: Wednesday, March 4, 2020 07:18
To: [REDACTED]@ec.europa.eu
Subject: Fwd: Altimune - coronavirus intranasal spray
vaccine development - need for resources

Dear Stella,

Here's the mail I was referring to at our lunch. Can you have a look at it, please?

Thank you and best regards,



Sent from my iPhone

Begin forwarded message:

From [REDACTED]
[REDACTED] <[\[REDACTED\]@presidiopartners.com](mailto:[REDACTED]@presidiopartners.com)>
Date: 3 March 2020 at 20:54:26 CET
To: "ROSSIDES Giorgos (CAB-KYRIAKIDES)"
[REDACTED] <[\[REDACTED\]@ec.europa.eu](mailto:[REDACTED]@ec.europa.eu)>
Cc: [REDACTED] (CAB-SEFCOVIC)"
[REDACTED] <[\[REDACTED\]@ec.europa.eu](mailto:[REDACTED]@ec.europa.eu)>,
[REDACTED] (CAB-SEFCOVIC)"
[REDACTED] <[\[REDACTED\]@ec.europa.eu](mailto:[REDACTED]@ec.europa.eu)>,
[REDACTED] (CAB-SEFCOVIC)"
[REDACTED] <[\[REDACTED\]@ec.europa.eu](mailto:[REDACTED]@ec.europa.eu)>,
[REDACTED] <[\[REDACTED\]@ipmlp.com](mailto:[REDACTED]@ipmlp.com)>
Subject: Altimmune - coronavirus intranasal spray vaccine development - need for resources

Dear Mr. Rossides,

I received your contact information from [REDACTED]. I wanted to bring to your attention a very promising development that requires EU's attention. It also requires EU's help to get the vaccine(s) to the hands of the European population asap – see below. As you are aware, multiple drug companies and institutes are racing to fight the coronavirus in the short-term (effective antivirals) and in the medium/long-term (vaccines). Please see an article link speaking about the key companies making progress on both fronts:

<https://www.investors.com/news/technology/coronavirus-vaccine-hunt-sends-biotech-companies-scrambling-treat-covid-19/>

One of them, Altimune (NASDAQ: ALT), small cap public biotech company based in Maryland near Washington D.C., USA, on Friday announced a successful early stage development of innovative single-dose intranasal vaccine for coronavirus. Very hopeful and it is creating quite a buzz in the scientific and business community. See the PR below.

<https://finance.yahoo.com/news/altimmune-completes-first-development-milestone-120010409.html>

To give you more detail, please find attached the presentation from yesterday's Cowen Healthcare Conference that received a positive response. First half of the presentation is dedicated to the vaccine. In a summary, the vaccine is specifically designed for global pandemics:

- S
i
n
g
l
e
- d
o
s
i
n
g
- I
n
t
r

a
n
a
s
a
l

s
p
r
a
y
,

i
.
e
.

n
o

n
e
e
d

f
o
r

i
n
j
e
c
t
i
o
n
s
o
S
e
l
f
-
a
d

m
i
n
i
s
t
r
a
t
i
o
n
,
i
.
e
.
n
o
n
e
e
d
t
o
g
o
t
o
t
h
e
c
l
i
n
i
c
t

o
g
e
t
a
n
i
n
j
e
c
t
i
o
n
,
w
h
i
c
h
i
s
a
n
a
d
d
i
t
i
o
n
a
l
r
i
s
k

a
n
d

e
x
p
o
s
u
r
e
o
B
r
o
a
d

a
c
t
i
v
a
t
i
o
n

o
f

a
n
t
i
b
o
d
y
,

m
u
c
o
s
a

I
a
n
d

c
e
l
l
u
l
a
r

i
m
m
u
n
e

s
y
s
t
e
m
s
o
N
o

n
e
e
d

f
o
r

c
o
l
d

s
t

o
r
a
g
e
-
i
.
e
.
e
a
s
y
t
o
t
r
a
n
s
p
o
r
t
a
n
d
a
d
m
i
n
i
s
t
e
r
o
R
o
b

u
s
t

m
a
n
u
f
a
c
t
u
r
i
n
g

p
r
o
f
i
l
e

-

e
a
s
y

t
o

s
c
a
l
e

t
o

m
i
l

I
i
o
n
(
s
)

o
f

v
a
c
c
i
n
e
s
,

e
t
c
.

In terms of specific help, when I spoke to [REDACTED], [REDACTED] identified several potential bottlenecks to get the vaccine on the market asap:

1. **Animal models for drug testing – primates.** We are helping Altimmune via SRI, formerly Stanford Research Institute, and others to find available, suitable primates the U.S.. Any help/contact with EU research centers for available, suitable primates would help.
2. **Manufacturing availability for active pharmaceutical**

ingredient (API) – key active matter in the vaccine. One of the issues is China as the key supplier of APIs globally and the network disruption. Getting an EU manufacturer onboard might be hugely helpful for the EU. The goal is to get the first batches produced by March 31 but the company needs to scale asap from there for human testing and large production.

3. **Bureaucracy** – FDA rules, EMA rules around clinical trials and approvals are not exactly suited for acute pandemic crises. Completely different approach, fast track / accelerated timelines and processes are needed. We will work FDA to get through red tape. Not sure what EMA is thinking on this topic.

An important note: Altimmune originally developed the platform for a potential influenza pandemic for the US government via a BARDA program; however, very few “investors” and only select public officials paid sufficient attention. Well, that completely changed now. As a fellow European, I want to make sure EU has access to all the best possible solutions so that this does not become just an American “solution” but a global solution. I believe it is important for EU to pursue multiple shots on goal in a speedy

manner to minimize the impact of coronavirus outbreak. It does not matter whether it is Sanofi, Moderna, Altimmune or someone else – I just want to make sure that no stone is unturned and we as a society pursue all promising pathways to get the economy back on track and out of panic mode.

As for my background, I am the [REDACTED] of Presidio Partners and [REDACTED] at IPM Group. I have been involved in venture capital investing in London and San Francisco for the past 13 years – this includes developing novel drugs such as novel antibiotics (eravacycline (Xerava) recently approved by FDA and EMA), vaccines and other critical therapeutics.

It would be great to have an introductory call and then I can hopefully rapidly make the intro to the Altimmune team. I am at your disposal but generally available mornings Pacific time (after 8:00am) /evening CET time (after 17:00) or late evenings Pacific time (23:00) / 8:00am CET. I am based in San Francisco. The company is currently focused on the work with U.S. government but the [REDACTED] already agreed to speak to the EU as well, if desired. [REDACTED] understands the global need for such a solution. Looking forward to connecting soon.

Kind regards,

[REDACTED]

Total Control Panel

[Login](#)

[REDACTED] [s@ipmlp.com](#) [Remove](#)
From: this
[REDACTED] [@ec.europa.eu](#) sender
from

my
allow
list

*You received this message because the
sender is on your allow list.*

Total Control Panel

[Login](#)

To: [redacted] [@ipmlp.com](#)

Message Score: 1

High (60): **Pass**

From: [redacted] [@ec.europa.eu](#)

My Spam Blocking Level: Medium

Medium (75): **Pass**

Low (90): **Pass**

[Block](#) this sender

[Block](#) ec.europa.eu

This message was delivered because the content filter score did not exceed your filter level.